Public market insider buying at Eupraxia Pharmaceuticals (T:EPRX)

Michael Wilmink, a Director, acquired 82,060 Common Shares on a direct ownership basis at prices ranging from US$1.157 to US$1.200 on June 8th, 2022. This represents a $122,632 investment into the company's shares and an account share holdings change of 61.0%.

Eupraxia Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its lead product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). EP-104IAR contains a solid core of the active ingredient Fluticasone Propionate (FP) with an outer layer of the biocompatible polymer, PVA. In addition to EP-104IAR, the Company is also developing a pipeline of earlier-stage long-acting formulations. It develops pipeline candidates for a range of indications, such as post-surgical pain (EP-105), and post-surgical site infections (EP-201). The Company has completed a phase I, double-blind, placebo-controlled clinical study at three sites in Canada.